
Harrow Health HROW
€ 32.19
2.35%
Geschäftsbericht 2025
hinzugefügt 02.03.2026
Harrow Health Langfristiger Schuldenstrom 2011-2026 | HROW
Langfristiger Schuldenstrom Jährlich Harrow Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 887 K | 497 K | 806 K | 723 K | 272 K | 580 K | 629 K | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 887 K | 272 K | 628 K |
Langfristiger Schuldenstrom anderer Aktien in der Arzneimittelhersteller
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
5.36 M | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
366 K | - | 10.11 % | $ 58.2 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
4.36 M | - | - | $ 754 M | ||
|
Catalent
CTLT
|
13 M | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
1.53 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
956 K | - | - | $ 28.9 M | ||
|
DURECT Corporation
DRRX
|
1.38 M | - | - | $ 50.1 M | ||
|
Alimera Sciences
ALIM
|
634 K | - | - | $ 142 M | ||
|
Athenex
ATNX
|
2.09 M | - | -23.39 % | $ 1.76 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
582 K | - | - | $ 2.06 B | ||
|
Evoke Pharma
EVOK
|
13.4 K | - | - | $ 36.6 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
357 K | $ 3.05 | -2.24 % | $ 42.9 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
3.91 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
914 K | - | 2.45 % | $ 38.1 M | ||
|
Sundial Growers
SNDL
|
35.5 M | $ 1.41 | 2.55 % | $ 3.37 M | ||
|
Bausch Health Companies
BHC
|
61 M | $ 5.71 | -0.26 % | $ 2.08 B | ||
|
Tilray
TLRY
|
2.47 M | $ 6.89 | 2.53 % | $ 4.26 B | ||
|
Aurora Cannabis
ACB
|
5.38 M | $ 3.53 | 1.44 % | $ 86.3 M | ||
|
Canopy Growth Corporation
CGC
|
7.46 M | $ 1.09 | 0.46 % | $ 117 M | ||
|
Veru
VERU
|
1.07 M | $ 2.39 | 0.42 % | $ 322 M | ||
|
Jupiter Wellness
JUPW
|
23.5 K | - | - | $ 33.6 M | ||
|
OrganiGram Holdings
OGI
|
1.03 M | $ 1.43 | 1.04 % | $ 402 M | ||
|
Lannett Company
LCI
|
2.06 M | - | 1.15 % | $ 7.11 M | ||
|
Viatris
VTRS
|
80.6 M | $ 13.97 | 0.98 % | $ 16.8 B | ||
|
Neoleukin Therapeutics
NLTX
|
3.05 M | - | - | $ 193 M | ||
|
Evolus
EOLS
|
2.53 M | $ 4.39 | 1.5 % | $ 283 M | ||
|
Emergent BioSolutions
EBS
|
3.5 M | $ 8.53 | 3.52 % | $ 437 M | ||
|
Organogenesis Holdings
ORGO
|
4.27 M | $ 2.47 | 3.57 % | $ 325 M | ||
|
Pacira BioSciences
PCRX
|
8.89 M | $ 23.72 | -1.41 % | $ 1.1 B | ||
|
PetIQ
PETQ
|
7.61 M | - | 1.64 % | $ 400 M | ||
|
ProPhase Labs
PRPH
|
301 K | - | - | $ 5.07 M | ||
|
Assertio Holdings
ASRT
|
240 K | $ 18.02 | 0.03 % | $ 115 M | ||
|
Radius Health
RDUS
|
613 K | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
1.1 M | - | -4.76 % | $ 65.3 M | ||
|
cbdMD
YCBD
|
98.7 K | $ 0.73 | -2.42 % | $ 3.15 M | ||
|
OptiNose
OPTN
|
911 K | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
483 K | $ 1.03 | 1.98 % | $ 51.4 M | ||
|
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
2.1 M | $ 8.24 | -1.73 % | $ 721 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
58 K | $ 2.17 | -7.66 % | $ 2.69 M | ||
|
Zomedica Corp.
ZOM
|
717 K | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
215 K | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
1.16 M | $ 0.91 | -2.76 % | $ 32.7 M | ||
|
Tricida
TCDA
|
2.74 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
71.6 K | $ 0.63 | -3.05 % | $ 2.7 M | ||
|
TherapeuticsMD
TXMD
|
975 K | $ 2.15 | 4.63 % | $ 24.9 M |